Added to YB: 2025-08-04
Pitch date: 2025-07-31
NOVO-B.CO [neutral]
Novo Nordisk A/S
+4.47%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 294.26
Price Target
514.37 (+67%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Novo Nordisk Just Lost $60 Billion in Market Cap
NOVO-B.CO (earnings update): 20% 5yr revenue CAGR (28% last 2yrs) at $44B scale; stock fell 26% on sales warning & CEO change. Growth slowing to 8-14% (from 16-24%), profit 10-16% (from 19-27%) due to US Ozempic/Wegovy slowdown & compounded GLP-1 issues. Strong ROIC ~40%, $10B capex. New CEO from int'l ops. Fwd P/E ~10, valuation 399 DKK vs 325 current.
Read full article (2 min)